A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.

The large study was conducted by Flávio A. Cadegiani, MD, MSc, PhD. Cadegiani is a board-certified endocrinologist with a master’s degree and doctorate degree in clinical endocrinology.

The peer-reviewed study was published on Wednesday by the online medical journal Cureus. The study was conducted on a strictly controlled population of 88,012 people from the city of Itajaí in Brazil.

Individuals who used ivermectin as prophylaxis or took the medication before being infected by COVID experienced significant reductions in death and hospitalization.

According to the study, those who took ivermectin regularly had a 92% reduction in their COVID death risk compared to non-users and 84% less than irregular users.

“The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users,” the study stated.